血浆可溶性肿瘤坏死因子受体浓度与住院后临床事件:ASSESS-AKI与ARID研究结果
在ASSESS-AKI与ARID前瞻性队列的1474例出院后3个月留存血浆样本的住院存活者中,血浆sTNFR1与sTNFR2每翻倍与肾脏病进展、心力衰竭及死亡的调整风险独立相关,且索引住院期间是否发生AKI不改变生物标志物与肾脏事件的关联。
要点
- 出院后3个月血浆sTNFR1与sTNFR2每翻倍,肾脏病进展调整HR分别为2.9与1.9。
- sTNFR1与sTNFR2每翻倍与心衰调整HR分别为1.9与1.5,与死亡调整HR分别为3.3与2.5。
- 索引住院期间AKI不修饰生物标志物与肾脏事件的关联。
核心结论
- 出院后3个月测定的血浆sTNFR1与sTNFR2独立关联临床事件,无论索引住院期间AKI状态如何。
- sTNFR1与sTNFR2可能有助于随访期间的患者风险分层。
研究设计与样本
- 前瞻性队列,纳入ASSESS-AKI与ARID研究中索引住院期间有或无AKI、且留有基线血清样本用于生物标志物测定的住院存活者。
- 共1474例参与者具有血浆生物标志物测定值。
主要发现
- 中位随访4.4年期间,19%发生肾脏病进展,14%后续发生心力衰竭,21%死亡。
- 肾脏结局:sTNFR1每翻倍调整HR 2.9(95% CI,2.2-3.9),sTNFR2每翻倍调整HR 1.9(95% CI,1.5-2.5)。
- 心力衰竭:sTNFR1每翻倍调整HR 1.9(95% CI,1.4-2.5),sTNFR2每翻倍调整HR 1.5(95% CI,1.2-2.0)。
- 死亡:sTNFR1每翻倍调整HR 3.3(95% CI,2.5-4.3),sTNFR2每翻倍调整HR 2.5(95% CI,2.0-3.1)。
- ARID研究中的结果在生物标志物与结局关联幅度方面定性相似。
临床怎么用
- 原文未据此给出推荐。
- 作者认为sTNFR1与sTNFR2可能有助于随访期间的患者风险分层。
局限性
- 不同生物标志物检测平台与AKI定义。
- 对其他种族人群的普遍性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The role of plasma soluble tumor necrosis factor receptor 1 (sTNFR1) and sTNFR2 in the prognosis of clinical events after hospitalization with or without acute kidney injury (AKI) is unknown. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: Hospital survivors from the ASSESS-AKI (Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury) and ARID (AKI Risk in Derby) studies with and without AKI during the index hospitalization who had baseline serum samples for biomarker measurements. PREDICTORS: We measured sTNFR1 and sTNFR2 from plasma samples obtained 3 months after discharge. OUTCOMES: The associations of biomarkers with longitudinal kidney disease incidence and progression, heart failure, and death were evaluated. ANALYTICAL APPROACH: Cox proportional hazard models. RESULTS: Among 1,474 participants with plasma biomarker measurements, 19% had kidney disease progression, 14% had later heart failure, and 21% died during a median follow-up of 4.4 years. For the kidney outcome, the adjusted HRs (AHRs) per doubling in concentration were 2.9 (95% CI, 2.2-3.9) for sTNFR1 and 1.9 (95% CI, 1.5-2.5) for sTNFR2. AKI during the index hospitalization did not modify the association between biomarkers and kidney events. For heart failure, the AHRs per doubling in concentration were 1.9 (95% CI, 1.4-2.5) for sTNFR1 and 1.5 (95% CI, 1.2-2.0) for sTNFR2. For mortality, the AHRs were 3.3 (95% CI, 2.5-4.3) for sTNFR1 and 2.5 (95% CI, 2.0-3.1) for sTNFR2. The findings in ARID were qualitatively similar in terms of the magnitude of association between biomarkers and outcomes. LIMITATIONS: Different biomarker platforms and AKI definitions; limited generalizability to other ethnic groups. CONCLUSIONS: Plasma sTNFR1 and sTNFR2 measured 3 months after hospital discharge were independently associated with clinical events regardless of AKI status during the index admission. sTNFR1 and sTNFR2 may assist with the risk stratification of patients during follow-up.
引用
- Coca SG, Vasquez-Rios G, Mansour SG, et al. Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies. Am J Kidney Dis. 2022. PMID: 36108888. doi:10.1053/j.ajkd.2022.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。